Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) started the day on Wednesday, with a price decrease of -1.12% at $281.49, before settling in for the price of $284.69 at the close. Taking a more long-term approach, ALNY posted a 52-week range of $141.98-$304.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 97.61%. Meanwhile, its Annual Earning per share during the time was 14.18%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 35.88%. This publicly-traded company’s shares outstanding now amounts to $128.38 million, simultaneously with a float of $127.23 million. The organization now has a market capitalization sitting at $36.14 billion. At the time of writing, stock’s 50-day Moving Average stood at $275.13, while the 200-day Moving Average is $205.43.
Alnylam Pharmaceuticals Inc (ALNY) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Alnylam Pharmaceuticals Inc’s current insider ownership accounts for 0.90%, in contrast to 94.02% institutional ownership. According to the most recent insider trade that took place on Aug 20 ’24, this organization’s Chief Executive Officer sold 15,000 shares at the rate of 280.00, making the entire transaction reach 4,200,000 in total value, affecting insider ownership by 73,441.
Alnylam Pharmaceuticals Inc (ALNY) Earnings and Revenue Records
Alnylam Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 35.88% and is forecasted to reach -1.36 in the upcoming year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Let’s observe the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). It’s Quick Ratio in the last reported quarter now stands at 2.93. The Stock has managed to achieve an average true range (ATR) of 7.26. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 15.41. Similarly, its price to free cash flow for trailing twelve months is now 113.33.
In the same vein, ALNY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.60, a figure that is expected to reach -0.92 in the next quarter, and analysts are predicting that it will be -1.36 at the market close of one year from today.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
If we take a close look at the recent performances of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), its last 5-days Average volume was 0.8 million that shows plunge from its year to date volume of 0.87 million. During the previous 9 days, stock’s Stochastic %D was recorded 8.95% While, its Average True Range was 7.07.
Raw Stochastic average of Alnylam Pharmaceuticals Inc (ALNY) in the period of the previous 100 days is set at 85.10%, which indicates a major rise in contrast to 12.36% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 28.22% that was lower than 59.34% volatility it exhibited in the past 100-days period.
